Abstract
In recent years, we have seen tremendous progress in our ability to achieve durable responses in patients with multiple myeloma. At the center of this progress, we have the development of 2 unrelated classes of drugs: proteasome inhibitors such as bortezomib and immunomodulatory drugs such as thalidomide and lenalidomide. The depth and durability of responses attained with these agents in the first-line setting has raised the possibility that they may be considered primary therapy. The Eastern Cooperative Oncology Group E1A05 clinical trial addresses the potential role of bortezomib and dexamethasone (VD) or VD plus lenalidomide (VRD) as primary first-line therapy. This clinical trial enrolls patients who have completed a dexamethasone-based induction (excluding patients using bortezomib). Assuming that most patients entering this clinical trial have been previously treated with thalidomide or lenalidomide, the trial will test whether switching to a proteasome inhibitor (VD arm) versus adding a proteasome inhibitor (VRD) results in superior longterm disease control. Patients entering this clinical trial will have deferred stem cell transplantation until the time of relapse. The primary endpoint of the trial is progression-free survival. By using an alkylator-free consolidation and reserving stem cell transplantation until the time of relapse, we hope that these treatment strategies will further prolong the survival of patients with myeloma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 315-317 |
| Number of pages | 3 |
| Journal | Clinical Lymphoma and Myeloma |
| Volume | 8 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 1 2008 |
Fingerprint
Keywords
- Consolidation therapy
- First-line therapy
- Proteasome inhibitor
- Quality of life
- Thalidomide analogue
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Hematology
Cite this
Consolidation therapy with bortezomib/lenalidomide/dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma : A randomized phase III trial. / Fonseca, Rafael; Rajkumar, S Vincent.
In: Clinical Lymphoma and Myeloma, Vol. 8, No. 5, 01.10.2008, p. 315-317.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Consolidation therapy with bortezomib/lenalidomide/dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma
T2 - A randomized phase III trial
AU - Fonseca, Rafael
AU - Rajkumar, S Vincent
PY - 2008/10/1
Y1 - 2008/10/1
N2 - In recent years, we have seen tremendous progress in our ability to achieve durable responses in patients with multiple myeloma. At the center of this progress, we have the development of 2 unrelated classes of drugs: proteasome inhibitors such as bortezomib and immunomodulatory drugs such as thalidomide and lenalidomide. The depth and durability of responses attained with these agents in the first-line setting has raised the possibility that they may be considered primary therapy. The Eastern Cooperative Oncology Group E1A05 clinical trial addresses the potential role of bortezomib and dexamethasone (VD) or VD plus lenalidomide (VRD) as primary first-line therapy. This clinical trial enrolls patients who have completed a dexamethasone-based induction (excluding patients using bortezomib). Assuming that most patients entering this clinical trial have been previously treated with thalidomide or lenalidomide, the trial will test whether switching to a proteasome inhibitor (VD arm) versus adding a proteasome inhibitor (VRD) results in superior longterm disease control. Patients entering this clinical trial will have deferred stem cell transplantation until the time of relapse. The primary endpoint of the trial is progression-free survival. By using an alkylator-free consolidation and reserving stem cell transplantation until the time of relapse, we hope that these treatment strategies will further prolong the survival of patients with myeloma.
AB - In recent years, we have seen tremendous progress in our ability to achieve durable responses in patients with multiple myeloma. At the center of this progress, we have the development of 2 unrelated classes of drugs: proteasome inhibitors such as bortezomib and immunomodulatory drugs such as thalidomide and lenalidomide. The depth and durability of responses attained with these agents in the first-line setting has raised the possibility that they may be considered primary therapy. The Eastern Cooperative Oncology Group E1A05 clinical trial addresses the potential role of bortezomib and dexamethasone (VD) or VD plus lenalidomide (VRD) as primary first-line therapy. This clinical trial enrolls patients who have completed a dexamethasone-based induction (excluding patients using bortezomib). Assuming that most patients entering this clinical trial have been previously treated with thalidomide or lenalidomide, the trial will test whether switching to a proteasome inhibitor (VD arm) versus adding a proteasome inhibitor (VRD) results in superior longterm disease control. Patients entering this clinical trial will have deferred stem cell transplantation until the time of relapse. The primary endpoint of the trial is progression-free survival. By using an alkylator-free consolidation and reserving stem cell transplantation until the time of relapse, we hope that these treatment strategies will further prolong the survival of patients with myeloma.
KW - Consolidation therapy
KW - First-line therapy
KW - Proteasome inhibitor
KW - Quality of life
KW - Thalidomide analogue
UR - http://www.scopus.com/inward/record.url?scp=58149350310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149350310&partnerID=8YFLogxK
U2 - 10.3816/CLM.2008.n.046
DO - 10.3816/CLM.2008.n.046
M3 - Article
C2 - 18854289
AN - SCOPUS:58149350310
VL - 8
SP - 315
EP - 317
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
SN - 2152-2669
IS - 5
ER -